Christian Brechot
Directeur/Membre du Conseil chez Fondation Mérieux
Profil
Christian Brechot is the founder of ScreenCell SA, which was founded in 2001.
He is currently the Vice Chairman at Global Virus Network, Director at Fondation Mérieux, Director at Institut Pasteur Korea Research Foundation, Director at Fondation Ophtalmologique Adolphe de Rothschild, Director at European Personalised Medicine Association, and Director at Rarecells Diagnostics SAS.
Dr. Brechot's former positions include being a Director at Transgene SA, Director at Biotheranostics, Inc., Director at bioMérieux SA from 2008 to 2012, General Director at Institut National de la Santé & de la Recherche Médicale from 2001 to 2007, Director at Drugs for Neglected Diseases initiative, President at Institut Pasteur from 2013 to 2017, Vice President-Medical & Scientific Affairs at Compagnie Merieux Alliance SAS, and Head-Clinical Department at Hopital Necker-Enfants Malades.
He obtained a doctorate degree from Université Paris 1 Panthéon-Sorbonne in 1985.
Postes actifs de Christian Brechot
| Sociétés | Poste | Début |
|---|---|---|
| Fondation Mérieux | Directeur/Membre du Conseil | - |
Fondation Ophtalmologique Adolphe de Rothschild
 Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Directeur/Membre du Conseil | - |
| European Personalised Medicine Association | Directeur/Membre du Conseil | - |
Institut Pasteur Korea Research Foundation
 Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Directeur/Membre du Conseil | - |
Global Virus Network
 Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Directeur/Membre du Conseil | - |
Rarecells Diagnostics SAS
 Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Directeur/Membre du Conseil | - |
Anciens postes connus de Christian Brechot
| Sociétés | Poste | Fin |
|---|---|---|
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | President | 13/10/2017 |
| BIOMÉRIEUX | Directeur/Membre du Conseil | 01/01/2012 |
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Corporate Officer/Principal | 01/01/2007 |
| ░░░░░░░░░░ ░░ | ░░░░░░░░░ | - |
| ░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Christian Brechot
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TRANSGENE | Health Technology |
| BIOMÉRIEUX | Health Technology |
| Entreprise privées | 13 |
|---|---|
Biotheranostics, Inc.
 Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Health Services |
Compagnie Merieux Alliance SAS
 Compagnie Merieux Alliance SAS Investment Trusts/Mutual FundsMiscellaneous Compagnie Mérieux Alliance SAS owns shares and interests in firms that manufactures, sells, and distributes medicines and other pharmaceutical products. The company is headquartered in Lyon, France. | Miscellaneous |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Commercial Services |
| Hopital Necker-Enfants Malades | |
| Fondation Mérieux | Miscellaneous |
Fondation Ophtalmologique Adolphe de Rothschild
Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Health Services |
| European Personalised Medicine Association | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Miscellaneous |
Drugs for Neglected Diseases initiative
 Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | Health Technology |
Institut Pasteur Korea Research Foundation
Institut Pasteur Korea Research Foundation BiotechnologyHealth Technology Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea. | Health Technology |
ScreenCell SA
 ScreenCell SA Miscellaneous Commercial ServicesCommercial Services ScreenCell SA provides access to circulating rare cells. It offers rare cell isolation solutions for medical and research applications. The company was founded by Patrizia Paterlini-Brechot, Ian Jones and Christian Brechot on April 11, 2001 and is headquartered in Sarcelles, France. | Commercial Services |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Commercial Services |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Technology Services |